YD Bio Ltd
Company Profile
Business description
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
Contact
No. 3, Xingnan Street
12th Floor
Nangang District
Taipei City115001
TWNT: +886 23820330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
stocks
Why it’s not all bad news for Flight Centre following downgrade
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.20 | 1.20 | -0.01% |
| CAC 40 | 8,384.87 | 46.74 | -0.55% |
| DAX 40 | 24,671.22 | 323.61 | -1.29% |
| Dow JONES (US) | 51,876.11 | 44.51 | -0.09% |
| FTSE 100 | 10,508.02 | 21.87 | -0.21% |
| HKSE | 22,671.86 | 405.05 | -1.76% |
| NASDAQ | 25,297.62 | 60.99 | -0.24% |
| Nikkei 225 | 69,360.88 | 3,005.46 | -4.15% |
| NZX 50 Index | 13,495.24 | 2.19 | 0.02% |
| S&P 500 | 7,354.02 | 3.47 | -0.05% |
| S&P/ASX 200 | 8,764.20 | 0.20 | 0.00% |
| SSE Composite Index | 4,027.26 | 93.02 | -2.26% |